Beyond Air reports $2.3M in preliminary Q3 2026 revenue

Beyond Air, Inc. (NASDAQ: XAIR) announced preliminary, unaudited revenue of approximately $2.3 million for the quarter ended September 30, 2026, according to a company press release. The figure represents a 30% increase compared with the quarter ended June 30, 2026, and a 27% increase compared with the same quarter in the prior year.

The company attributed the revenue to continued adoption of its first-generation LungFit PH system, a cylinder-free nitric oxide delivery device approved by the FDA for treating term and near-term neonates with hypoxic respiratory failure.

"Our strong revenue growth in the quarter ended September 30, 2026 reflects continued adoption of LungFit PH and the value hospitals see in our cylinder-free nitric oxide technology," said Robert Goodman, Chief Executive Officer of Beyond Air.

The company's second-generation LungFit PH system remains under FDA review via a PMA supplement process. Revenue guidance for calendar year 2026 is reaffirmed at $8 million, excluding any contribution from the second-generation system. Revenue guidance for calendar year 2027 is reaffirmed at $16 million to $18 million, which includes anticipated revenue from the second-generation system pending FDA approval.

The preliminary revenue figure is unaudited and based on management estimates. It remains subject to completion of financial closing procedures and review by the company's independent registered public accounting firm. Full financial results for the quarter ended September 30, 2026 are expected to be reported in November 2026.

You May Also Be Interested In

• Southern Copper Corp. (SCCO) Tops Q3 EPS by 19c
• Cleveland-Cliffs (CLF) PT Raised to $18 at B.Riley
• Lexaria completes enrollment in semaglutide oral delivery study